Amarin Corporation plc · NASDAQ:AMRN
Amarin — Investor Presentation (November 2005)
23 slides from Amarin's investor presentation, November 2005
Slide 1: The Future in Mind
CORPORATION PLC THE FUTURE IN MIND
Slide 2: Safe Harbour
SAFE HARBOUR DISCLOSURE NOTICE: The information contained in this document is as of November, 2005. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking
Slide 3: Neuroscience company focused on novel drugs for CNS disorders
Neuroscience company focused on research, development and commercialization of novel drugs for CNS disorders COMMERCIAL HIGHLIGHTS KEY FACTS Late stage development pipeline • UK based, US focused • Risk managed portfolio • 26 employees Lead product – Miraxion • NASDAQ (ticker: AMRN) • PIII for Hunti
Slide 4: Management Team
MANAGEMENT TEAM Rick Stewart Chief Executive Officer Alan Cooke Chief Financial Officer Dr Mehar Manku Head of Research & Development Dr Tony Clarke VP Clinical Development Darren Cunningham EVP Strategic Development David Boal Business Development Director 4
Slide 5: Neurology Focus
NEUROLOGY FOCUS U.S. CNS MARKET $41bn Significant unmet medical need Market - double digit annual growth Neurology Aging U.S. demographics $12 bn Physicians covered by a modest size sales force Leverage management knowledge and U.S. NEUROLOGISTS 7,200 experience Previously established U.S. High neur
Slide 6: Strategy
STRATEGY Develop and directly market neurology products for U.S. Partner neuroscience pipeline for indications outside neurology and markets outside U.S. In-license additional novel neurology compounds for U.S. Goal: Leading neurology company 6
Slide 7: Product Pipeline: Amarin Commercialisation
PRODUCT PIPELINE: AMARIN COMMERCIALISATION DEVELOPMENT P/C I II III Miraxion Huntington's disease (US) Miraxion Undisclosed indication Comb. Lipid Neurodegeneration Amarin has an active in-licensing program for development stage neurology products for the U.S. market. Current development status 7
Slide 8: Product Pipeline: Out-licensing/Partnering
PRODUCT PIPELINE: OUT-LICENSING/PARTNERING DEVELOPMENT P/C I II III Miraxion Huntington's disease (EU*) Miraxion Depressive disorders LAX-201 Major Depression in women LAX-202 Multiple Sclerosis Fatigue (EU) IP CNS indications *Miraxion for HD in EU: • Already partnered for major EU market with Scil
Slide 9: Miraxion
MIRAXIONTM Miraxion is a semi-synthetic, highly purified derivative of (all- cis)-5,8,11,14,17- eicosapentaenoic acid (ethyl-EPA) Ethyl-EPA based prescription compounds are already approved by the regulatory authorities in Japan and the U.S. for cardiovascular indications Mechanism of action: • Regu
Slide 10: Huntington's Disease ('HD')
HUNTINGTON’S DISEASE (‘HD’) Devastating neurodegenerative disease No effective treatment currently available to patients Caused by high level of CAG repeats in specific genes Typically CAG repeats >36 denotes presence of HD Symptoms after age 30 with death in 10 to 25 years Severe movement disorders
Slide 11: Miraxion for HD: Initial Phase III
MIRAXION FOR HD: INITIAL PHASE III Large multi-centre 135-patient 12-month double-blind placebo-controlled trial Primary endpoint: Miraxion versus placebo on total motor score – 4 (‘TMS-4’) sub-scale of UHDRS Effect on primary endpoint, TMS-4: Group Patients Significance Intent to Treat (ITT) 135 No
Slide 12: Miraxion for HD: CAG < 44 Group
MIRAXION FOR HD: CAG < 44 GROUP Significant in ITT and PP groups at 6 months and 12 months Positive CAG data consistent across centres Group represents 65-70% of all HD patients Time course of TMS-4, ITT (LOCF), CAG ≤ 44 40 Placebo 35 Miraxion 30 25 6 month, p = 0.025 20 12 month, p = 0.029 15 12 ba
Slide 13: Miraxion for HD: CAG < 44 Group
MIRAXION FOR HD: CAG < 44 GROUP GROUP BASELINE CHANGE TO 12 M 25.4 + 11.8 0.0 + 6.8 (0%) ITT Placebo n=32 ITT Miraxion n=35 23.1 + 9.4 -3.5 + 7.5 (-15.2%) P-value of difference NS 0.029 PP Placebo n=22 24.5 + 12.6 +1.4 + 7.5 (+5.7%) PP Miraxion n=22 22.5 + 10.8 -5.1 + 7.9 (-22.7%) P-value of differe
Slide 14: Miraxion for HD: Phase III Strategy
MIRAXION FOR HD : PHASE III STRATEGY • Special Protocol Assessment (“SPA”) in place Consideration Initial Trial New Trials Patient entry criteria • All comers • CAG < 44 and less severe Protocol compliance • Too few centres (6) • 70 centres • Too few evaluations • More evaluations • 6 month extensio
Slide 15: Depression
Depressive Disorders in the U.S. DEPRESSION (approx 19 m) Annual U.S. sales of Bipolar Disorder antidepressants c$13 billion 12% Major Depression 65% to 75% not effectively treated 52% Miraxion offers a different and complementary mechanism of Other action to SSRI’s 36% Modification of neuronal memb
Slide 16: Miraxion for Depression: Investigator-led Phase IIa studies
MIRAXION FOR DEPRESSION Three Investigator led Phase IIa studies with Miraxion achieved statistical significance: Investigators Trial Details Indication Results N=20 Treatment 2g/d or placebo unresponsive Belmaker(I) p<0.05 for 4 wks depression N=75 Depression 1 or 2g/d or placebo for In bipolar Fra
Slide 17: Miraxion for Depression: Melancholic Features
MIRAXION FOR DEPRESSION: MELANCHOLIC FEATURES Peet & Horrobin Phase IIa study also achieved statistical significance in primary endpoint Post-hoc data analysis completed on three Amarin led phase IIa studies Identified that Miraxion showed a significant clinical benefit in patients with melancholic
Slide 18: Miraxion for Depression: Summary
MIRAXION FOR DEPRESSION: SUMMARY Phase IIa studies show promising results (adjunctive and monotherapy) Offers different and complementary mechanism of action to SSRI’s Identification of subgroup with melancholic features allows more accurate targeting of potentially responsive patients Patents grant
Slide 19: Intellectual Property for Miraxion
INTELLECTUAL PROPERTY FOR MIRAXION Miraxion in HD Miraxion in Depression • Orphan drug designation • Patent 40266 (granted) 7 years market exclusivity in US, Depression, Schizophrenia, valid up to 10 years in Europe until 2017, US and EU • Patent 40390 (pending) • Patent 40390 (pending) Use of Mirax
Slide 20: Financial Summary
FINANCIAL SUMMARY Q3-05 Q2-05 Q1-05 $ $ $ Operating Loss 4.6m 5.7m 3.3m • Increase driven by R&D investment Capitalisation Sep 30 • Cash position $13.7m • No debt • Common Shares1 51.4m • Options (avg exercise price $3.90) 4.5m • Warrants (avg exercise price $2.51) 0.8m 1Investors in May financing h
Slide 21: Near Term Potential Milestones
NEAR TERM POTENTIAL MILESTONES Amarin Commercialisation Out-licensing/Partnering Miraxion for HD Miraxion for Depression 2006 • First patient in Q3 05 • Last patient in Q2 06 Miraxion for HD • Last patient out Q4 06 (remaining EU markets) 2005/6 • Data available Late 06/Early 07 LAX-201 for depressi
Slide 22: Investment Rationale
INVESTMENT RATIONALE Valuable near term product pipeline Lead product, Miraxion in Phase III development: Under SPA and with Fast track designation Leveraged extensive data of initial Phase III HSG/Euro HD Established safety profile Multiple programs in Phase II and earlier Active in-licensing and o
Slide 23: The Future in Mind
CORPORATION PLC THE FUTURE IN MIND